MX344885B - Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. - Google Patents

Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.

Info

Publication number
MX344885B
MX344885B MX2008014321A MX2008014321A MX344885B MX 344885 B MX344885 B MX 344885B MX 2008014321 A MX2008014321 A MX 2008014321A MX 2008014321 A MX2008014321 A MX 2008014321A MX 344885 B MX344885 B MX 344885B
Authority
MX
Mexico
Prior art keywords
composition
rosuvastatin calcium
obtaining
product obtained
lipids
Prior art date
Application number
MX2008014321A
Other languages
English (en)
Other versions
MX2008014321A (es
Inventor
Estrada Flores Luis
Lizeth Maya Ayala Kenia
Original Assignee
Psicofarma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psicofarma S A De C V filed Critical Psicofarma S A De C V
Priority to MX2008014321A priority Critical patent/MX344885B/es
Priority to EP09825024A priority patent/EP2347758A4/en
Priority to PCT/MX2009/000081 priority patent/WO2010053343A1/es
Priority to JP2011535525A priority patent/JP2012508230A/ja
Priority to NZ593349A priority patent/NZ593349A/xx
Priority to CA2744820A priority patent/CA2744820C/en
Priority to BRPI0921019A priority patent/BRPI0921019A2/pt
Priority to US13/128,329 priority patent/US20120269890A1/en
Publication of MX2008014321A publication Critical patent/MX2008014321A/es
Publication of MX344885B publication Critical patent/MX344885B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe una composición de resuvastatina cálcica y su proceso de obtención, en la cual por su procedimiento de obtención y la selección de los componentes de la composición no se requiere de sales de fosfato tribásico para ser estable y que también tiene una adecuada biodisponibilidad, es útil para lograr una disminución de los niveles de lípidos y/o colesterol en el cuerpo, así como el método de fabricación de esta composición.
MX2008014321A 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. MX344885B (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP09825024A EP2347758A4 (en) 2008-11-10 2009-07-29 METHOD FOR OBTAINING A COMPOSITION OF ROSUVASTATIN AND CALCIUM AND THE PRODUCT OBTAINED
PCT/MX2009/000081 WO2010053343A1 (es) 2008-11-10 2009-07-29 Proceso para la obtención de una composición de rosuvastatina cálcica y producto obtenido
JP2011535525A JP2012508230A (ja) 2008-11-10 2009-07-29 ロスバスタチンカルシウム組成物の取得方法及び得られた産物
NZ593349A NZ593349A (en) 2008-11-10 2009-07-29 Process for obtaining a composition of rosuvastatin calcium and product obtained
CA2744820A CA2744820C (en) 2008-11-10 2009-07-29 Process for obtaining a rosuvastatin calcium composition and obtained product
BRPI0921019A BRPI0921019A2 (pt) 2008-11-10 2009-07-29 processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido
US13/128,329 US20120269890A1 (en) 2008-11-10 2009-07-29 Process for obtaining a rosuvastatin calcium composition and obtained product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.

Publications (2)

Publication Number Publication Date
MX2008014321A MX2008014321A (es) 2010-06-07
MX344885B true MX344885B (es) 2017-01-10

Family

ID=42153048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.

Country Status (8)

Country Link
US (1) US20120269890A1 (es)
EP (1) EP2347758A4 (es)
JP (1) JP2012508230A (es)
BR (1) BRPI0921019A2 (es)
CA (1) CA2744820C (es)
MX (1) MX344885B (es)
NZ (1) NZ593349A (es)
WO (1) WO2010053343A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643693T3 (es) * 2011-05-20 2017-11-23 Astrazeneca Uk Limited Composición farmacéutica de rosuvastatina cálcica
CA2845301A1 (en) * 2011-08-15 2013-02-21 Technion Research And Development Foundation Ltd. Combinations of corroles and statins
JP6161867B2 (ja) * 2011-11-17 2017-07-12 株式会社アドバンテスト 滑沢剤の展延解析装置、方法、プログラム、記録媒体
EP2787987B1 (de) * 2011-12-08 2016-06-01 Hexal AG Neue pharmazeutische statin-zusammensetzung
JP2016098187A (ja) * 2014-11-19 2016-05-30 ニプロ株式会社 口腔内崩壊錠
JP6108635B2 (ja) * 2015-05-14 2017-04-05 ダイト株式会社 ロスバスタチン含有口腔内速崩壊錠
JP6167192B2 (ja) * 2016-01-19 2017-07-19 株式会社アドバンテスト 滑沢剤の展延解析装置、方法、プログラム、記録媒体
CN110151725B (zh) * 2019-06-26 2021-06-18 海南通用三洋药业有限公司 一种稳定的瑞舒伐他汀钙胶囊剂及其制备方法
CN110974793A (zh) * 2019-12-26 2020-04-10 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙片剂及其制备方法
CN113230223B (zh) * 2021-05-13 2023-04-07 宜昌人福药业有限责任公司 阿托伐他汀钙薄膜包衣片的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
DE10204336A1 (de) * 2002-02-01 2003-08-14 Merck Patent Gmbh Verwendung von Mehrschichtpigmenten im Lebensmittel- und Pharmabereich
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
BRPI0407518A (pt) * 2003-02-20 2006-02-14 Bpsi Holdings Inc sistemas de revestimento de pelìcula perolada e substratos revestidos por eles
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070053892A1 (en) * 2005-09-07 2007-03-08 Everett Laboratories, Inc. Methods and kits for co-administration of nutritional supplements
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
JP2010519216A (ja) * 2007-02-15 2010-06-03 ファイザー・リミテッド Ｃｃｒ５拮抗薬のための医薬組成物および方法
CL2008003154A1 (es) * 2007-10-26 2009-10-23 Eurofarma Laboratorios LTDA Proceso de obtencion de un extracto estandarizado de aleuterites moluccana; extracto estandarizado de aleurites moluccana; composicion farmaceutica que comprende el extracto; uso del extracto para tratar condiciones de dolor.

Also Published As

Publication number Publication date
WO2010053343A1 (es) 2010-05-14
BRPI0921019A2 (pt) 2015-12-22
JP2012508230A (ja) 2012-04-05
CA2744820C (en) 2016-03-01
CA2744820A1 (en) 2010-05-14
US20120269890A1 (en) 2012-10-25
MX2008014321A (es) 2010-06-07
EP2347758A4 (en) 2012-04-25
EP2347758A1 (en) 2011-07-27
NZ593349A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
MX2008014321A (es) Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010033587A3 (en) Methods for treating progressive multiple sclerosis
EP2252717A4 (en) STEEL, METHOD FOR MANUFACTURING STEEL DRAFT, AND METHOD FOR MANUFACTURING STEEL COMPONENT
MX338201B (es) Bacterias acidolacticas de postacidificion baja.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX2011001679A (es) Derivados de flavina.
SI2143688T1 (sl) Postopek za pripravo vodne suspenzije kalcijevega karbonata in pridobljena suspenzija, kakor tudi postopek za njeno uporabo
ATE475437T1 (de) Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
WO2011028423A3 (en) Method for producing a stable oxidizing biocide
ZA201100842B (en) Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2012057454A3 (ko) 골 이식재 제조방법 및 그로 인해 제조된 골 이식재
WO2014072982A3 (en) Tools and systems for solid form and graft implantation
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
MX2012008098A (es) Proceso para la produccion de dioxido de cloro.
IN2015KN00212A (es)
MX2009009490A (es) Profarmacos novedosos.
AP2012006173A0 (en) Process and reagents for the inhibition or reduction of scale formation during phosphoric acid production.
WO2007084858A3 (en) Biomimetic hydroxyapatite synthesis
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
EP2426234A4 (en) CALCIUM PHOSPHATE COMPLEX AND PROCESS FOR PRODUCING THE SAME
WO2011144733A3 (en) Dynamic double-circuit in-line heater
WO2010035284A3 (en) An improved process for the preparation of rosuvastatin calcium
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration